title: Questions concerning the clinical translation of cell-based interventions under an innovation pathway.
abstract: Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.
authors.affiliation: Berman Institute of Bioethics, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Sugarman
mesh_terms: D017408:Guidelines as Topic; D006805:Human Experimentation / Q000941:ethics*; D006801:Humans; D017146:Models, Organizational; D012107:Research Design; D033581:Stem Cell Transplantation / Q000941:ethics*; D057170:Translational Research, Biomedical / Q000941:ethics* / Q000458:organization & administration